| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHKb |
| Uniprot No | Q9Y259 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-395aa |
| 氨基酸序列 | MAAEATAVAGSGAVGGCLAKDGLQQSKCPDTTPKRRRASSLSRDAERRAYQWCREYLGGAWRRVQPEELRVYPVSGGLSNLLFRCSLPDHLPSVGEEPREVLLRLYGAILQGVDSLVLESVMFAILAERSLGPQLYGVFPEGRLEQYIPSRPLKTQELREPVLSAAIATKMAQFHGMEMPFTKEPHWLFGTMERYLKQIQDLPPTGLPEMNLLEMYSLKDEMGNLRKLLESTPSPVVFCHNDIQEGNILLLSEPENADSLMLVDFEYSSYNYRGFDIGNHFCEWVYDYTHEEWPFYKARPTDYPTQEQQLHFIRHYLAEAKKGETLSQEEQRKLEEDLLVEVSRYALASHFFWGLWSILQASMSTIEFGYLDYAQSRFQFYFQQKGQLTSVHSSS |
| 预测分子量 | 45,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CHK相关重组蛋白研究的代表性文献，供参考：
1. **文献名称**：*"Expression and purification of recombinant human checkpoint kinase 1 (CHK1) for inhibitor screening"*
**作者**：Chen X, et al.
**摘要**：该研究报道了人源CHK1激酶结构域的重组表达与纯化方法，通过大肠杆菌系统获得高活性蛋白，并用于高通量抑制剂筛选，为癌症治疗药物开发提供基础。
2. **文献名称**：*"Structural insights into the catalytic mechanism of CHK2 kinase through recombinant protein crystallography"*
**作者**：Oliver AW, et al.
**摘要**：利用昆虫细胞表达系统获得重组CHK2激酶结构域，通过X射线晶体学解析其三维结构，揭示了ATP结合位点及底物识别机制，为靶向设计提供结构基础。
3. **文献名称**：*"Functional characterization of recombinant CHKβ in DNA damage response pathways"*
**作者**：Sato S, et al.
**摘要**：研究通过哺乳动物细胞表达系统制备重组CHKβ蛋白，证实其在DNA损伤应答中与ATM/ATR激酶的相互作用，并调控细胞周期检查点激活。
**备注**：若特指“CHKb”为其他蛋白(如代谢相关CKβ)，建议提供更多上下文以便精准检索。
**Background of CHKβ Recombinant Protein**
CHKβ (Checkpoint kinase beta), a member of the serine/threonine kinase family, plays a critical role in cellular responses to DNA damage and replication stress. It functions within conserved signaling pathways, primarily interacting with upstream regulators like ATM/ATR kinases to coordinate cell cycle checkpoints, DNA repair, and apoptosis. CHKβ is structurally characterized by a conserved kinase domain and regulatory regions that mediate phosphorylation-dependent activation. Upon DNA damage, CHKβ is activated through phosphorylation, enabling it to inhibit cyclin-dependent kinases (CDKs) and arrest the cell cycle, allowing time for repair or triggering programmed cell death if damage is irreparable.
Recombinant CHKβ proteins are engineered using expression systems (e.g., *E. coli*, mammalian cells) to produce high-purity, functional proteins for research and therapeutic development. These proteins retain enzymatic activity and are utilized to study CHKβ's role in cancer biology, as dysregulation of CHKβ signaling is linked to tumorigenesis and chemotherapy resistance. Additionally, recombinant CHKβ serves as a tool for screening kinase inhibitors, aiding drug discovery for cancer therapies targeting checkpoint pathways. Its application extends to elucidating mechanisms of genome stability, cell survival, and interactions with oncogenes or tumor suppressors like p53.
The development of CHKβ recombinant proteins underscores their importance in advancing molecular oncology and personalized medicine, offering insights into DNA damage response networks and potential biomarkers for cancer treatment.
×
